Learn About COAGADEX

COAGADEX is a high-purity product that contains more than 94% factor X.1

It is the first and only treatment specifically for people with factor X deficiency.


Until recently, the treatments available were designed for other diseases and contain larger amounts of other proteins, such as factors II and IX, in addition to factor X.2

Taking these extra proteins when you don’t need them can cause blood clots that may block blood vessels and cause serious injury (for example: stroke or blood clots in the lung or leg).3

Other treatments for factor X deficiency
94% Factor X

With COAGADEX, you get the factor X you need without a lot of other proteins that you don’t need.

COAGADEX is a high-purity product that contains more than 94% factor X.1

Indications and Usage for COAGADEX

COAGADEX, a plasma-derived blood coagulation factor X concentrate, is indicated in adults and children with hereditary factor X deficiency for:

  • Routine prophylaxis to reduce the frequency of bleeding episodes
  • On-demand treatment and control of bleeding episodes
  • Perioperative management of bleeding in patients with mild and moderate hereditary factor X deficiency

Limitation of Use

Perioperative management of bleeding in major surgery in patients with severe hereditary factor X deficiency has not been studied.

To learn more about COAGADEX, talk to your healthcare provider or join our mailing list

Contraindication for COAGADEX

COAGADEX is contraindicated in patients with known hypersensitivity to any of the components of the product.

Important Safety Information for COAGADEX

Allergic type hypersensitivity reactions, including anaphylaxis, are possible with COAGADEX. If symptoms occur, patients should discontinue use of the product immediately, contact their physician, and administer appropriate treatment.

The formation of neutralizing antibodies (inhibitors) to factor X is a possible complication in the management of individuals with factor X deficiency. Carefully monitor patients taking COAGADEX for the development of inhibitors by appropriate clinical observations and laboratory tests.

COAGADEX is made from human plasma and may contain infectious agents, e.g. viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases, vCJD or CJD, have been associated with the use of COAGADEX.

In clinical studies, the most common adverse reactions (frequency ≥5% of subjects) with COAGADEX were infusion site erythema, infusion site pain, fatigue and back pain.

Please see complete Prescribing Information for COAGADEX.

References: 1. Data on file, BPL-RD050-0515. 2. Medical and Scientific Advisory Council (MASAC) of the National Hemophilia Foundation. MASAC Document #253. https://www.hemophilia.org/Researchers-Healthcare-Providers/Medical-and-Scientific-Advisory-Council-MASAC/MASAC-Recommendations/MASAC-Recommendations-Concerning-Products-Licensed-for-the-Treatment-of-Hemophilia-and-Other-Bleeding-Disorders. Accessed April 11, 2019. 3. Menegatti M, Peyvandi F. Factor X deficiency. Semin Thromb Hemost. 2009;35:407-415.